Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache

The FDA Wednesday granted a Breakthrough Therapy Designation for Lilly’s Emgality for its ability to prevent cluster headaches, and the drugmaker now plans to file for approval in that use by the end of the year.